Anushuya Devi Kasi
Research Subjects
Anushuya Devi Kasi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Stergios K. Doumouchtsis
Department of Obstetrics and Gynaecology, Epsom and St. Helier University Hospitals NHS Trust, Dorking Rd, Epsom KT187EG, UK
2 shared publications - Azar Khunda
Department of Obstetrics and Gynaecology, Urogynaecology Unit, St. George's University Hospitals NHS Foundation Trust, London, SW17 0QT, UK.
1 shared publication - Despina Perrea
Laboratory of Experimental Surgery and Surgical Research ‘N.S. Christeas’, Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece
1 shared publication - Vasilios Pergialiotis
1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
1 shared publication
Latest Publications
- 30 July 2016
- Published by Springer Nature
- p. 249-270
Prediction, Risk Assessment, and Prevention of Childbirth Trauma
- 30 July 2016
- Published by Springer Nature
- p. 249-270
Prediction, Risk Assessment, and Prevention of Childbirth Trauma
- 26 July 2015
- Published by Springer Nature in International Urogynecology Journal
- Vol. 27 (3) , 367-375
Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature
Polyacrylamide hydrogel (PAHG, Bulkamid®) is one of several injectable agents currently used for the treatment of women with urinary stress incontinence. Although bulking agents appear to have lower efficacy rates compared to other surgical treatments, current evidence based on large prospective or comparative studies as well as systematic reviews is limited. The purpose of this study was to conduct a systematic review on the efficacy of PAHG in the treatment of female patients with stress urinary incontinence with regard to reproducibility, feasibility, safety and clinical outcome. We searched MEDLINE (1966–2015), Scopus (2004–2015), POPLINE (1974–2015) and ClinicalTrials.gov (2008–2015) along with reference lists of electronically retrieved studies. Observational studies, prospective, retrospective and randomized controlled studies were included. Two reviewers independently selected studies, assessed the risk of bias and tabulated data to structured forms. We included 8 studies, which enrolled a total of 767 patients who received treatment with PAHG. We found that 186 of 767 women (24.3 %, range 12–35 %) required reinjection in order to achieve adequate efficacy. The most frequent adverse effects were pain at the site of injection (4–14 %) and urinary tract infections (3–7 %). Both the number of incontinence episodes/24 h and the number of ml/24 h were significantly reduced 1 year following treatment and the quality of life of patients was significantly improved. PAHG is a safe intervention for treating women with stress urinary incontinence, but repeat injections are often required. Further research is mandated in the field in order to compare its efficacy to other bulking agents.
- 26 July 2015
- Published by Springer Nature in International Urogynecology Journal
- Vol. 27 (3) , 367-375
Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature
Polyacrylamide hydrogel (PAHG, Bulkamid®) is one of several injectable agents currently used for the treatment of women with urinary stress incontinence. Although bulking agents appear to have lower efficacy rates compared to other surgical treatments, current evidence based on large prospective or comparative studies as well as systematic reviews is limited. The purpose of this study was to conduct a systematic review on the efficacy of PAHG in the treatment of female patients with stress urinary incontinence with regard to reproducibility, feasibility, safety and clinical outcome. We searched MEDLINE (1966–2015), Scopus (2004–2015), POPLINE (1974–2015) and ClinicalTrials.gov (2008–2015) along with reference lists of electronically retrieved studies. Observational studies, prospective, retrospective and randomized controlled studies were included. Two reviewers independently selected studies, assessed the risk of bias and tabulated data to structured forms. We included 8 studies, which enrolled a total of 767 patients who received treatment with PAHG. We found that 186 of 767 women (24.3 %, range 12–35 %) required reinjection in order to achieve adequate efficacy. The most frequent adverse effects were pain at the site of injection (4–14 %) and urinary tract infections (3–7 %). Both the number of incontinence episodes/24 h and the number of ml/24 h were significantly reduced 1 year following treatment and the quality of life of patients was significantly improved. PAHG is a safe intervention for treating women with stress urinary incontinence, but repeat injections are often required. Further research is mandated in the field in order to compare its efficacy to other bulking agents.